8-叔丁基腺嘌呤 | 50609-20-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 8-叔丁基腺嘌呤
• 中文别名: 8-叔-丁基-7H-嘌呤-6-胺
• 英文名称: 8-tert-butyl-7(9)H-purin-6-ylamine
• 英文别名: 8-tert.-Butyl-9H-adenin；8-tert-Butyladenine；8-tert-butyl-7H-purin-6-amine
• CAS: 50609-20-6
• 化学式: C₉H₁₃N₅
• 分子量: 191.236
• InChiKey: LSOOEJSTVYZUEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  80.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  4,5,6-三氨基嘧啶硫酸盐 、 三甲基乙酸 以16%的产率得到8-叔丁基腺嘌呤
  参考文献：
  名称：

  嘌呤衍生物作为人红细胞膜磷脂酰肌醇4-激酶的竞争性抑制剂。

  摘要：

  在一系列嘌呤衍生物和类似物中，已经研究了获得有效的，可穿透细胞的人红细胞PI 4-激酶抑制剂（相对于ATP具有竞争性）的可能性。嘌呤核对于结合到ATP位点不是必不可少的，但具有合成易接近其衍生物的优势。发现嘌呤中的最佳取代方式是6-位的电子释放取代基（例如氨基，如腺嘌呤1），在8位或最好在9位是紧密的亲脂基团，表明N-1孤对的重要性以及8和9取代基对结合的疏水作用。合成的最有效的抑制剂是9-环己基腺嘌呤（54），其表观Ki值为3.7 microM。

  DOI：

  10.1021/jm00170a005

文献信息

• Shape memory polymers
  申请人：Anthamatten Mitchell L.

  公开号：US20080177303A1

  公开（公告）日：2008-07-24

  The present disclosure relates to Shape Memory Polymers (SMP's) comprising function groups that allow the polymers to be elastically deformed, utilized in the elastically deformed state, and subsequently returned to the original polymorphic shape.

  本公开涉及形状记忆聚合物（SMP），其中包含允许聚合物弹性变形的功能基团，可在弹性变形状态下使用，并随后返回到原始的多态形状。
• Shape Memory Polymers
  申请人：Anthamatten Mitchell L.

  公开号：US20110251364A1

  公开（公告）日：2011-10-13

  The present disclosure relates to Shape Memory Polymers (SMP's) comprising function groups that allow the polymers to be elastically deformed, utilized in the elastically deformed state, and subsequently returned to the original polymorphic shape.

  本公开涉及具有功能基团的形状记忆聚合物（SMP），这些功能基团使聚合物能够弹性变形，在弹性变形状态下使用，并随后返回到原始的多形态形状。
• Inhibitors of phosphatidylinositol 3-kinase gamma
  申请人：AstraZeneca AB

  公开号：US10858355B2

  公开（公告）日：2020-12-08

  There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3Kδ) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

  本文公开了某些新型化合物（包括其药学上可接受的盐）、 抑制磷脂酰肌醇 3- 激酶γ（PI3Kδ）活性的化合物，它们在治疗和/或预防包括呼吸系统疾病（如哮喘和慢性阻塞性肺病（COPD））在内的临床疾病中的用途，它们在治疗中的使用，含有它们的药物组合物，以及制备此类化合物的工艺。
• NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA
  申请人：AstraZeneca AB

  公开号：US20200299289A1

  公开（公告）日：2020-09-24

  There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (P13Kδ) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
• INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA
  申请人：AstraZeneca AB

  公开号：US20210047312A1

  公开（公告）日：2021-02-18

  There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3Kδ) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.